Description: Covalon Technologies Ltd. is a researcher, developer, manufacturer and marketer of medical products that manage patient outcomes and save lives in the areas of wound care, infection management and surgical procedures. The Company offers platform technologies: Collagen matrix; Antimicrobial silicone adhesive and Medical coating technology. The collagen matrix platform is used to manufacture products that treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. The antimicrobial silicone adhesive platform is the basis for a range of pre-surgical, post surgical and vascular access products that are designed to kill any bacteria or yeast that comes into contact with the antimicrobial silicone. The coating technology is a grafting from process, which utilizes photo-polymerization to create active grafting sites.
Home Page: www.covalon.com
COV Technical Analysis
1660 Tech Avenue
Mississauga,
ON
L4W 5S7
Canada
Phone:
905 568 8400
Officers
Name | Title |
---|---|
Mr. Brian E. Pedlar | Pres, CEO & Director |
Simon Smith | Chief Exec. Officer of Covalon Technologies (Europe) Ltd. |
Gerry Arambula | Pres of Covalon Technologies AG Ltd. |
Dr. Valerio DiTizio | Co-Founder, Chief Scientific Officer & VP |
Mr. Jason F. Gorel | Interim Chief Financial Officer |
Ms. Elaine Zhang | VP of Operations |
Mr. Ron Hebert | Sr. VP of Marketing |
Mr. Greg Leszczynski | VP of HR |
Mr. Mark Doolittle | Sr. VP of Commercial Sales |
Mr. Hamed Abbasian | VP of Bus. Devel. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
Forward PE: | 0 |
---|---|
Trailing PE: | 41.1667 |
Price-to-Book MRQ: | 2.1895 |
Price-to-Sales TTM: | 2.954 |
IPO Date: | |
Fiscal Year End: | September |
Full Time Employees: | 0 |